The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 18 May 2004, www.theannals.com, DOI 10.1345/aph.1D516.
 The Annals of Pharmacotherapy: Vol. 38, No. 7, pp. 1202-1205. DOI 10.1345/aph.1D516
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malek-Ahmadi, P.
Right arrow Articles by Ghandour, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malek-Ahmadi, P.
Right arrow Articles by Ghandour, E.

Bupropion for Treatment of Interferon-Induced Depression

Parviz Malek-Ahmadi, MD

Professor, Department of Neuropsychiatry, School of Medicine, Health Sciences Center, Texas Tech University, Lubbock, TX

Elias Ghandour, MD

Clinical Assistant Professor, Department of Internal Medicine, School of Medicine, Health Sciences Center, Texas Tech University

Reprints: Parviz Malek-Ahmadi MD, Department of Neuropsychiatry, School of Medicine, Texas Tech University Health Sciences Center, 3601 Fourth St., Lubbock, TX 79430-9103, fax 806/743-4250, parviz.malekahmadi{at}ttuhsc.edu

OBJECTIVE: To report the effect of bupropion in a patient with interferon (IFN)-induced depression and review the use of antidepressants for treatment of depressive symptoms associated with IFN therapy.

CASE SUMMARY: A 43-year-old white woman with chronic hepatitis C and severe IFN-induced depression was treated with sustained-release bupropion initiated at 150 mg/day for 7 days and 100 mg twice daily thereafter. The dosage was increased again, to 350 mg/day when depressive symptoms recurred. While receiving that dose and continuing IFN treatment, she reported significant improvement in her depressive symptoms without experiencing any adverse effects.

DISCUSSION: There is limited evidence suggesting that IFNs decrease central serotonergic transmission. There are several published reports on the use of selective serotonin-reuptake inhibitors for the treatment of IFN-induced depression. However, controlled studies are needed to assess the efficacy of serotonergic and noradrenergic antidepressants in IFN-treated patients with depressive symptoms.

CONCLUSIONS: Sustained-release bupropion might be of potential benefit in patients with interferon-induced depression.

Key Words: bupropion, sustained-release, depression, hepatitis C, interferon alfa

Published Online, May 18, 2004. www.theannals.com, DOI 10.1345/aph.1D516


This article has been cited by other articles:


Home page
 PsychosomaticsHome page
C. C. Crone, G. M. Gabriel, and A. DiMartini
An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist
Psychosomatics, June 1, 2006; 47(3): 188 - 205.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. A Hughes and S. D Shafran
Chronic Hepatitis C Virus Management: 2000-2005 Update
Ann. Pharmacother., January 1, 2006; 40(1): 74 - 82.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.